This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Araki, S. Articles by Lokeshwar, B. L. Search for Related Content PubMed PubMed Citation Articles by Araki, S. Articles by Lokeshwar, B. L.

Interleukin-8 Is a Molecular Determinant of Androgen Independence and Progression in Prostate Cancer

Departments of ¹ Urology, ² Cell Biology and Anatomy, ³ Radiation Oncology, and ⁴ Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida

Requests for reprints: Bal L. Lokeshwar, Department of Urology (M-800), School of Medicine, University of Miami, P.O. Box 016960, Miami, FL 33101. Phone: 305-243-1012; Fax: 305-243-9724; E-mail: blokeshw{at}miami.edu.

The proinflammatory chemokine interleukin-8 (IL-8) is undetectable in androgen-responsive prostate cancer cells (e.g., LNCaP and LAPC-4), but it is highly expressed in androgen-independent metastatic cells, such as PC-3. In this report, we show IL-8 functions in androgen independence, chemoresistance, tumor growth, and angiogenesis. We stably transfected LNCaP and LAPC-4 cells with IL-8 cDNA and selected IL-8–secreting (IL8-S) transfectants. The IL8-S transfectants that secreted IL-8 at levels similar to that secreted by PC-3 cells (100–170 ng/10⁶ cells) were characterized. Continuous or transient exposure of LNCaP and LAPC-4 cells to IL-8 reduced their dependence on androgen for growth and decreased sensitivity (>3.5x) to an antiandrogen. IL-8–induced cell proliferation was mediated through CXCR1 and was independent of androgen receptor (AR). Quantitative PCR, immunoblotting, and transfection studies showed that IL8-S cells or IL-8–treated LAPC-4 cells exhibit a 2- to 3-fold reduction in PSA and AR levels, when compared with vector transfectants. IL8-S cells expressed 2- to 3-fold higher levels of phospho-EGFR, src, Akt, and nuclear factor B (NF-B) and showed increased survival when treated with docetaxel. This increase was blocked by NF-B and src inhibitors, but not by an Akt inhibitor. IL8-S transfectants displayed a 3- to 5-fold increased motility, invasion, matrix metalloproteinase-9 and vascular endothelial growth factor production. LNCaP IL8-S cells grew rapidly as tumors, with increased microvessel density and abnormal tumor vasculature when compared with the tumors derived from their vector-transfected counterparts. Therefore, IL-8 is a molecular determinant of androgen-independent prostate cancer growth and progression. [Cancer Res 2007;67(14):6854–62]

This article has been cited by other articles:

				N. Shamaladevi, D. A. Lyn, D. O. Escudero, and B. L. Lokeshwar CXC Receptor-1 Silencing Inhibits Androgen-Independent Prostate Cancer Cancer Res., November 1, 2009; 69(21): 8265 - 8274. [Abstract] [Full Text] [PDF]

				J. A. Watson, C. J. Watson, A.-M. McCrohan, K. Woodfine, M. Tosetto, J. McDaid, E. Gallagher, D. Betts, J. Baugh, J. O'Sullivan, et al. Generation of an epigenetic signature by chronic hypoxia in prostate cells Hum. Mol. Genet., October 1, 2009; 18(19): 3594 - 3604. [Abstract] [Full Text] [PDF]

				D. Vindrieux, P. Escobar, and G. Lazennec Emerging roles of chemokines in prostate cancer Endocr. Relat. Cancer, September 1, 2009; 16(3): 663 - 673. [Abstract] [Full Text] [PDF]

				S. Tseng-Rogenski and M. Liebert Interleukin-8 is essential for normal urothelial cell survival Am J Physiol Renal Physiol, September 1, 2009; 297(3): F816 - F821. [Abstract] [Full Text] [PDF]

				Y. Xu, S. Josson, F. Fang, T. D. Oberley, D. K. St. Clair, X. S. Wan, Y. Sun, V. Bakthavatchalu, A. Muthuswamy, and W. H. St. Clair RelB Enhances Prostate Cancer Growth: Implications for the Role of the Nuclear Factor-{kappa}B Alternative Pathway in Tumorigenicity Cancer Res., April 15, 2009; 69(8): 3267 - 3271. [Abstract] [Full Text] [PDF]

				I. Kogan-Sakin, M. Cohen, N. Paland, S. Madar, H. Solomon, A. Molchadsky, R. Brosh, Y. Buganim, N. Goldfinger, H. Klocker, et al. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1 Carcinogenesis, April 1, 2009; 30(4): 698 - 705. [Abstract] [Full Text] [PDF]

				D. J.J. Waugh and C. Wilson The Interleukin-8 Pathway in Cancer Clin. Cancer Res., November 1, 2008; 14(21): 6735 - 6741. [Abstract] [Full Text] [PDF]

				C. Wilson, T. Wilson, P. G. Johnston, D. B. Longley, and D. J.J. Waugh Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells Mol. Cancer Ther., September 1, 2008; 7(9): 2649 - 2661. [Abstract] [Full Text] [PDF]

				D. J. Caruso, A. J.K. Carmack, V. B. Lokeshwar, R. C. Duncan, M. S. Soloway, and B. L. Lokeshwar Osteopontin and Interleukin-8 Expression is Independently Associated with Prostate Cancer Recurrence Clin. Cancer Res., July 1, 2008; 14(13): 4111 - 4118. [Abstract] [Full Text] [PDF]

				A. Seaton, P. Scullin, P. J. Maxwell, C. Wilson, J. Pettigrew, R. Gallagher, J. M. O'Sullivan, P. G. Johnston, and D. J. J. Waugh Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation Carcinogenesis, June 1, 2008; 29(6): 1148 - 1156. [Abstract] [Full Text] [PDF]